Work

Epitope-guided Mycobacterium tuberculosis Zmp1 peptide-associated outer membrane vesicles enhance humoral responses to a heterologous antigen SARS-CoV-2 RBD-S2

Year: 2026
Type: article
Abstract: Enhancing robust antibody responses for applications ranging from vaccine development to commercial antibody production depends on the strategic combination of highly immunogenic antigens and delivery systems that effectively amplify antigen-specific humoral immunity. We observed high titers of Mycobacterium tuberculosis Zmp1 (Mtb Zmp1)-specific antibodies in patients with active tuberculosis (TB), with similarly strong responses in paucibacillary pulmonary and extrapulmonary TB, highlighting the broad humoral immunogenicity of Mtb Zmp1 in our previous studies. We hypothesized that immunoinformatics-guided Zmp1-derived peptides encompassing overlapping predicted B-cell and CD4 + T-cell determinants would improve this antigenic potential and, when delivered in an immunostimulatory platform, could also enhance responses to a co-delivered heterologous antigen. To test this approach, selected Zmp1 peptides or full-length Zmp1 were fused to Escherichia coli ClyA for generating recombinant E. coli ΔnlpI-derived outer membrane vesicles (OMVs), providing an intrinsically immunostimulatory delivery platform. The engineered OMVs formed stable nanoscale vesicles and efficiently incorporated the Zmp1 antigens. All Zmp1-engineered OMV formulations elicited significantly higher Zmp1-specific antibody responses than empty OMVs, confirming that the humoral responses were driven by the Zmp1 antigens. Notably, OMVs associated with the C-terminal Zmp1 region (OMV-CT) generated the strongest Zmp1-specific humoral response, establishing this epitope-enriched region as a potent antigenic component. We next tested whether the Zmp1-engineered OMVs could enhance immunity to a heterologous candidate antigen, SARS-CoV-2 RBD-S2. OMV-CT+RBD-S2 produced the highest RBD-S2-specific antibody titers among the formulations tested, with increased IgG1, IgG2b, and total IgG titers from day 28 that remained elevated through days 42 and 64. This enhanced antibody response was accompanied by relatively higher IL-4 than IFN-γ production and increased CD19 + CD273 + memory B cells and CD4 + CD44 + CD62L + memory T cells, consistent with a Th2-associated response and development of immunological memory. Together, these findings demonstrate that selected Zmp1-derived peptides function as potent antigenic determinants and, when presented within an immunostimulatory OMV platform, can enhance antibody responses to a co-delivered heterologous antigen. These findings highlight the potential of Zmp1 peptide-OMV formulations as versatile adjuvant platforms for promoting robust humoral immunity, supporting the broader use of these formulations with dose and peptide optimization wherever robust humoral immunity is targeted.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236807681
FWCI:
Cites: 35
Cited by:
Related to: 10
Parts: 1